DEK expression is controlled by E2F and deregulated in diverse tumor types

Maria Stella Carro, Fabio Mario Spiga, Micaela Quarto, Valentina Di Ninni, Sara Volorio, Myriam Alcalay, Heiko Müller

Research output: Contribution to journalArticle

85 Citations (Scopus)

Abstract

Deregulation of the retinoblastoma (pRB) tumor suppressor pathway associated with aberrant activity of E2F transcription factors is frequently observed in human cancer. Microarray based analyses have revealed a large number of potential downstream mediators of the tumor suppressing activity of pRB, including DEK, a fusion partner of CAN found in a subset of acute myeloid leukaemia (AML) patients carrying a (6; 9) translocation. Here we report that the expression of DEK is under direct control of E2F transcription factors. Chromatin immunoprecipitation assays show that the DEK promoter is bound by endogenous E2F in vivo. The DEK promoter is transactivated by E2F and mutation of E2F binding sites eliminates this effect. Expression levels of DEK in human tumors have been investigated by tissue micro array analysis. We find that DEK is overexpressed in many solid tumors such as colon cancer, larynx cancer, bladder cancer, and melanoma.

Original languageEnglish
Pages (from-to)1202-1207
Number of pages6
JournalCell Cycle
Volume5
Issue number11
Publication statusPublished - Jun 1 2006

Fingerprint

Tumors
E2F Transcription Factors
Laryngeal Neoplasms
Neoplasms
Urinary Bladder Neoplasms
Deregulation
Tissue Array Analysis
Microarrays
Retinoblastoma
Chromatin Immunoprecipitation
Chromatin
Assays
Microarray Analysis
Fusion reactions
Acute Myeloid Leukemia
Colonic Neoplasms
Binding Sites
Tissue
Melanoma
Mutation

Keywords

  • Cancer
  • DEK
  • E2F
  • Overexpression
  • Tissue microarray

ASJC Scopus subject areas

  • Cell Biology
  • Biochemistry
  • Molecular Biology

Cite this

Carro, M. S., Spiga, F. M., Quarto, M., Di Ninni, V., Volorio, S., Alcalay, M., & Müller, H. (2006). DEK expression is controlled by E2F and deregulated in diverse tumor types. Cell Cycle, 5(11), 1202-1207.

DEK expression is controlled by E2F and deregulated in diverse tumor types. / Carro, Maria Stella; Spiga, Fabio Mario; Quarto, Micaela; Di Ninni, Valentina; Volorio, Sara; Alcalay, Myriam; Müller, Heiko.

In: Cell Cycle, Vol. 5, No. 11, 01.06.2006, p. 1202-1207.

Research output: Contribution to journalArticle

Carro, MS, Spiga, FM, Quarto, M, Di Ninni, V, Volorio, S, Alcalay, M & Müller, H 2006, 'DEK expression is controlled by E2F and deregulated in diverse tumor types', Cell Cycle, vol. 5, no. 11, pp. 1202-1207.
Carro MS, Spiga FM, Quarto M, Di Ninni V, Volorio S, Alcalay M et al. DEK expression is controlled by E2F and deregulated in diverse tumor types. Cell Cycle. 2006 Jun 1;5(11):1202-1207.
Carro, Maria Stella ; Spiga, Fabio Mario ; Quarto, Micaela ; Di Ninni, Valentina ; Volorio, Sara ; Alcalay, Myriam ; Müller, Heiko. / DEK expression is controlled by E2F and deregulated in diverse tumor types. In: Cell Cycle. 2006 ; Vol. 5, No. 11. pp. 1202-1207.
@article{093c0fcd6b94430c92f6f11820e4a3a1,
title = "DEK expression is controlled by E2F and deregulated in diverse tumor types",
abstract = "Deregulation of the retinoblastoma (pRB) tumor suppressor pathway associated with aberrant activity of E2F transcription factors is frequently observed in human cancer. Microarray based analyses have revealed a large number of potential downstream mediators of the tumor suppressing activity of pRB, including DEK, a fusion partner of CAN found in a subset of acute myeloid leukaemia (AML) patients carrying a (6; 9) translocation. Here we report that the expression of DEK is under direct control of E2F transcription factors. Chromatin immunoprecipitation assays show that the DEK promoter is bound by endogenous E2F in vivo. The DEK promoter is transactivated by E2F and mutation of E2F binding sites eliminates this effect. Expression levels of DEK in human tumors have been investigated by tissue micro array analysis. We find that DEK is overexpressed in many solid tumors such as colon cancer, larynx cancer, bladder cancer, and melanoma.",
keywords = "Cancer, DEK, E2F, Overexpression, Tissue microarray",
author = "Carro, {Maria Stella} and Spiga, {Fabio Mario} and Micaela Quarto and {Di Ninni}, Valentina and Sara Volorio and Myriam Alcalay and Heiko M{\"u}ller",
year = "2006",
month = "6",
day = "1",
language = "English",
volume = "5",
pages = "1202--1207",
journal = "Cell Cycle",
issn = "1538-4101",
publisher = "Landes Bioscience",
number = "11",

}

TY - JOUR

T1 - DEK expression is controlled by E2F and deregulated in diverse tumor types

AU - Carro, Maria Stella

AU - Spiga, Fabio Mario

AU - Quarto, Micaela

AU - Di Ninni, Valentina

AU - Volorio, Sara

AU - Alcalay, Myriam

AU - Müller, Heiko

PY - 2006/6/1

Y1 - 2006/6/1

N2 - Deregulation of the retinoblastoma (pRB) tumor suppressor pathway associated with aberrant activity of E2F transcription factors is frequently observed in human cancer. Microarray based analyses have revealed a large number of potential downstream mediators of the tumor suppressing activity of pRB, including DEK, a fusion partner of CAN found in a subset of acute myeloid leukaemia (AML) patients carrying a (6; 9) translocation. Here we report that the expression of DEK is under direct control of E2F transcription factors. Chromatin immunoprecipitation assays show that the DEK promoter is bound by endogenous E2F in vivo. The DEK promoter is transactivated by E2F and mutation of E2F binding sites eliminates this effect. Expression levels of DEK in human tumors have been investigated by tissue micro array analysis. We find that DEK is overexpressed in many solid tumors such as colon cancer, larynx cancer, bladder cancer, and melanoma.

AB - Deregulation of the retinoblastoma (pRB) tumor suppressor pathway associated with aberrant activity of E2F transcription factors is frequently observed in human cancer. Microarray based analyses have revealed a large number of potential downstream mediators of the tumor suppressing activity of pRB, including DEK, a fusion partner of CAN found in a subset of acute myeloid leukaemia (AML) patients carrying a (6; 9) translocation. Here we report that the expression of DEK is under direct control of E2F transcription factors. Chromatin immunoprecipitation assays show that the DEK promoter is bound by endogenous E2F in vivo. The DEK promoter is transactivated by E2F and mutation of E2F binding sites eliminates this effect. Expression levels of DEK in human tumors have been investigated by tissue micro array analysis. We find that DEK is overexpressed in many solid tumors such as colon cancer, larynx cancer, bladder cancer, and melanoma.

KW - Cancer

KW - DEK

KW - E2F

KW - Overexpression

KW - Tissue microarray

UR - http://www.scopus.com/inward/record.url?scp=33744905317&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33744905317&partnerID=8YFLogxK

M3 - Article

VL - 5

SP - 1202

EP - 1207

JO - Cell Cycle

JF - Cell Cycle

SN - 1538-4101

IS - 11

ER -